Chong Kun Dang Pharmaceutical Corp.

KSE 185750.KS

Chong Kun Dang Pharmaceutical Corp. Inventory for the year ending December 31, 2023: USD 200.78 M

Chong Kun Dang Pharmaceutical Corp. Inventory is USD 200.78 M for the year ending December 31, 2023, a -5.90% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

Chong Kun Dang Pharmaceutical Corp. Inventory for the year ending December 31, 2022 was USD 213.36 M, a 13.44% change year over year.
Chong Kun Dang Pharmaceutical Corp. Inventory for the year ending December 31, 2021 was USD 188.09 M, a 10.42% change year over year.
Chong Kun Dang Pharmaceutical Corp. Inventory for the year ending December 31, 2020 was USD 170.35 M, a 33.12% change year over year.
Chong Kun Dang Pharmaceutical Corp. Inventory for the year ending December 31, 2019 was USD 127.97 M, a 12.19% change year over year.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

KSE: 185750.KS

Chong Kun Dang Pharmaceutical Corp.

CEO	Mr. Young-Joo Kim
IPO Date	Dec. 6, 2013
Location	South Korea
Headquarters	8, Chungjeong-ro
Employees	2,286
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods Drugstores & Retail Pharmacies

Description

Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years